Jinsai Pharmaceutical’s new drug officially approved for clinical trials to improve micropenis in children!
February 24, 2026
Source: drugdu
27
On February 24, the CDE website showed that GenSci141 ointment , submitted by Jinsai Pharmaceutical , was approved for clinical trials. It is indicated for improving micropenis in children caused by hypergonadotropic hypogonadism, 5α-reductase 2 deficiency, congenital adrenal hyperplasia with reduced androgen synthesis, and idiopathic causes. The registration categories are 2.2 and 2.4.
GenSci141 ointment is a dihydrotestosterone ointment developed by Jinsai Pharmaceutical . It mainly works by paracrine secretion within target tissues, targeting and promoting penile tissue growth and development.
According to publicly available information, there are currently no approved drugs worldwide specifically for micropenis in children, indicating a significant unmet clinical need. If successful, GenSci141 ointment could become the world's first drug specifically for micropenis in children.
https://mp.weixin.qq.com/s/lKYLBl1EyMWSjlHehOE0Kw
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Aohong Pharmaceutical | Drug registration application for Motomidyl Hydrochloride Injection accepted by CDE February 24, 2026
- Hansoh Pharmaceutical’s blockbuster new drug has been approved for marketing in the European Union! February 24, 2026
- Frontier Biotechnologies Enters Global Licensing Collaboration with GlaxoSmithKline for Small Nucleic Acid Drugs February 24, 2026
- Rising Star in Oral Weight Loss! Hengrui’s GLP 1R/GIPR Agonist Succeeds in Phase II Study February 13, 2026
- adjuvant therapy for breast cancer February 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
